From a Canadian public healthcare system perspective, ofatumumab is cost effective against all currently approved and reimbursed disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis (RRMS), and dominant compared with all disease-modifying therapies with a first-line indication, except glatiramer acetate.

Ofatumumab’s cost effectiveness, alongside its high efficacy and favorable safety profile, demonstrate its value as an early treatment option in RRMS.